ArticleAmerican journal of hematology2024

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.

Garima Pandey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.